ORYZON realizará múltiples actividades corporativas en conferencias internacionales en abril
The biopharmaceutical company has been invited to participate or attend different events of reference within the biotechnology industry.
Oryzon Genomics S.A, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in April.
Oryzon has been invited to attend the Investing in Oncology Forum 2024, which will be held at the IVA Konferenscenter in Stockholm (Sweden) on April 10, where the company will provide a corporate update at 14:45 CET and will hold one-on-one meetings with global investors and pharmaceutical companies.
Oryzon will attend the Van Lanschot Life Sciences Conference, which will take place in Amsterdam (Netherlands) on April 16-17, where the company will maintain meetings with investors
Oryzon will attend the Swiss Biotech Day 2024, which will be held at the Markthalle in Basel (Switzerland) on April 22-23. The company will hold one-on-one meetings with pharmaceutical companies.
Oryzon has been invited to the LSX World Congress 2024, which will be held in London (UK) on April 29-30. Oryzon will take part in the keynote plenary panel entitled “The inflation Reduction Act and its Potential Impact On EU Biotech & Pharma Companies: Demystifying the Future” on April 29 at 16:20 BST